Med-Tech Innovation July 29, 2024
Oliver Johnson

Otsuka and Health Innovation Oxford & Thames Valley (Oxford HIN) have announced a collaboration to evaluate the implementation and integration of a new digital therapeutic (DTx), CARE for MDD, intended to treat major depressive disorder.

Otsuka Pharmaceutical Europe Ltd. and Otsuka Pharmaceuticals (U.K.) Ltd. (Otsuka) are collaborating with Health Innovation Oxford & Thames Valley (Oxford HIN) to evaluate the implementation and integration of a new digital therapeutic (DTx), CARE for MDD, intended to support the treatment of major depressive disorder (MDD), more commonly referred to as clinical depression, or depressive disorder.

The companies say the collaboration aims to support patients living with depressive disorder by developing solutions beyond medication, and will combine Oxford HIN’s network and expertise in mental health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Mental Health, Patient / Consumer, Provider, Technology
Related Articles:
988 Mental Health Hotline Failed to Boost Service Offerings
Suicide hotline has not led to increased mental health service access: Study
Private Equity Investors Are Still Laser-Focused on Behavioral Health Care
Private Equity in Behavioral Health: Compliance Champions or Cost-Cutting Villains?
Private equity-backed company acquires New York behavioral provider

Share This Article